Savara Pharmaceuticals

Share price catalysts: June 2019

Why investors should question Savara's excuse

With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.

April 16, 2019

Savara hopes to take a leaf out of Insmed’s book

Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.

May 30, 2018

Savara blazes the reverse merger trail

March 12, 2018

ACC – Savara shrugs as Mast fades into the past